Stada and alvotech launch uzpruvo, the first approved ustekinumab biosimilar to stelara, across europe

Stada and alvotech launch uzpruvo, the first approved ustekinumab biosimilar to stelara, across europe launch of european-made uzpruvo in europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and rheumatology creates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently estimated at approximately €2.4 billion ustekinumab is the second immunology biosimilar brought to market through the partnership between stada and alvotech, following the 2022 launch of the hukyndra high-concentration adalimumab brand bad vilbel, germany and reykjavik, iceland – 22 july 2024 –stada and alvotech have launched uzpruvo®, the first approved biosimilar to stelara® in europe, across a majority of european countries. this includes the largest markets in the region, where pricing and reimbursement approvals have been secured for market entry.
ALVO Ratings Summary
ALVO Quant Ranking